Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: A multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial

1. Välimäiki, M.J.
2. Farrerons-Minguella, J.
3. Halse, J.
4. Kröger, H.
5. Maroni, M.
6. Mulder, H.
7. Muñoz-Torres, M.
8. Sääf, M.
9. Snorre Øfjord, E.